Sample Answer for HIM 2433 MDC Reporting Adverse Reaction Question Included After Question<\/strong><\/h2>\nDescription<\/h2>\n\nRead the instructions associated with the form for adverse reactions. You will note that the form indicates that the patient had an adverse reaction to a drug.<\/p>\n
Your job is to review the health record document, determine, and report the adverse reaction. Pay close attention to what is required of D1 & D4. Put your name in textbox “G” as the reporter.<\/p>\n
DISCHARGE<\/span>\u00a0SUMMARY<\/span>
\nPATEL, SHERRY<\/span>\u00a0#0267852<\/span>
\nDATE OF<\/span>
\nADMISSION:<\/span>\u00a002\/26\/XX<\/span>\u00a0DATE OF DISCHARGE:<\/span>\u00a003\/01\/XX<\/span>
\nFINAL DIAGNOSES:<\/span>
\n1.<\/span>\u00a0Left femoral neck fracture<\/span>
\n2.<\/span>\u00a0Paroxysmal Atrial Fibrillation, converted<\/span>
\nto sinus rhythm<\/span>
\n3.<\/span>\u00a0Urinary tract infection<\/span>
\n4.<\/span>\u00a0Rash due to Bactrim<\/span>
\n5.<\/span>\u00a0Mild Dementia<\/span>
\n6.<\/span>\u00a0Hypertensive Heart Disease with<\/span>
\nhypercholestrolemia<\/span>
\n7.<\/span>\u00a0History of Strokes (Cerebrovascular<\/span>
\nAccidents [CVA])<\/span>
\nJustification of Admission<\/span>
\nThis 77<\/span>–<\/span>year<\/span>–<\/span>old female presented to the ER after falling at her beach<\/span>
\nhome.<\/span>\u00a0Upon examination, the patient complains of inability to walk and severe<\/span>
\nhip pain.<\/span>\u00a0H<\/span>er past medical history reveals multiple strokes with dementia<\/span>
\nresiduals and heart disease. X<\/span>–<\/span>rays revealed a femoral neck fracture.<\/span>\u00a0Patient<\/span>
\ncurrent medications include Coumadin, Diovan, OsCal, Magnesium chloride,<\/span>
\nMegace, Levothroid, Remeron, and Lipitor<\/span>.<\/span>
\nHospital Course<\/span>
\nThe patient was admitted and Dr. Black an Orthopedic surgeon was consulted.<\/span>
\nOn the evening of 02\/26, an open reduction and internal fixation repair was<\/span>
\nperformed on the left hip.<\/span>\u00a0During the surgery there was a great deal of bloo<\/span>d<\/span>
\nloss that was replaced with three units of packed cells. The patient transfused<\/span>
\ntwo units packed cells without incidence.<\/span>\u00a0Coumadin was placed on hold and the<\/span>
\npatient was placed on Lasix.<\/span>
\nPostoperatively the patient developed an atrial fibrillation whic<\/span>h was controlled<\/span>
\nwith Toprol, Digoxin, and Verapamil.<\/span>\u00a0Three days postoperatively, the patient<\/span>
\nbegin to spike fevers of 101<\/span>\u00a0\u030a.\u00a0Cultures were taken of the blood and urine.<\/span>\u00a0The<\/span>
\npatient<\/span>\u00a0developed a urinary tract<\/a> infection growing over 100,000 colonies of E.<\/span>
\nColi bacteria. The patient was started on Bactrim p.o. however the patient<\/span>
\ncomplained of a rash over her mid<\/span>–<\/span>abdomen.<\/span>\u00a0Calamine lotion was applied to the<\/span>
\nrash using cotton swabs.<\/span>\u00a0The medication was switched to Keflex.<\/span>\u00a0The patient is<\/span>
\nafebrile and currentl<\/span>y receiving physical therapy<\/a>.<\/span>\u00a0She will be transferred to<\/span>
\nMiami Dade College Rehab Center where she will continue her therapy.<\/span><\/p>\n![\"HIM](\"https:\/\/nursingassignmentcrackers.com\/wp-content\/uploads\/2023\/03\/HIM-2433-MDC-Reporting-Adverse-Reaction-Question-300x138.png\")
HIM 2433 MDC Reporting Adverse Reaction Question<\/figcaption><\/figure>\nClick here to ORDER an A++ paper from our Verified MASTERS and DOCTORATE WRITERS:HIM 2433 MDC Reporting Adverse Reaction Question<\/strong><\/a><\/span><\/p>\nDischarge Medications<\/span>
\nThe patient will be discharged to rehab with Lactulose 60 mg p.r.n. q.h.s.,<\/span>
\nDarvocet 1 tablet q..6h p.r.n.<\/span>, Lovothroid 0.075 mg q.d., Lipitor 10 mg q.d.,<\/span>
\nRemeron 15 md q.hs., OsCal 500+D 1 t.i.d., Coumadin 3 mg q.d., Diovan 160<\/span>
\nmg q.d., Magnesium chloride 400<\/span>–<\/span>1 t.i.d., Neutra<\/span>–<\/span>Phos 1 tab q.i.d., Megace 100<\/span>
\nmg q.i.d., Toprol 50<\/span>–<\/span>mg q.d.<\/span>
\nMark J. Curry, MD__<\/span>\u00a0Mark J. Curry, MD<\/span>
\nAttending Physician<\/span><\/p>\n<\/div>\nReset Form DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration The FDA Safety Information and Adverse Event Reporting Program Form FDA 3500 Form Approved: OMB No. 0910-0291, Expires: 06-30-2025 See PRA statement on page 6. FDA USE ONLY Triage unit sequence # FDA Rec. Date For VOLUNTARY reporting of adverse events, product problems and product use\/medication errors Note: For date prompts of \u201cdd-mmm-yyyy\u201d please use 2-digit day, 3-letter month abbreviation, and 4-digit year; for example, 01-Jan-1900. A. PATIENT INFORMATION 1. Patient Identifier (In confidence) 3a. Sex: Enter the patient\u2019s sex at birth (the sex that a person has or was assigned to at birth). Male Undifferentiated Female Decline to answer 4. Weight 2. Age or Date of Birth (e.g., 01-Jan-1900) Year(s) Week(s) Month(s) Day(s) 3b. Gender: Enter the patient\u2019s current gender (how the patient thinks of themself). lb 5. Ethnicity (Check one) Hispanic\/Latino kg Not Hispanic\/Latino Cisgender man\/boy (gender corresponds with birth sex) Transgender woman\/trans woman\/ male-to-female (MTF) Cisgender woman\/girl (gender corresponds with birth sex) Other gender category; please specify: Transgender man\/trans man\/ female-to-male (FTM) Decline to answer 6. Race (check all that apply) American Indian\/Alaska Native Asian Black or African American Native Hawaiian\/ Other Pacific Islander White B. ADVERSE EVENT, PRODUCT PROBLEM 1. Type of Report (check all that apply) 2. Outcome Attributed to Adverse Event (check all that apply) Adverse Event Death \u2013 Date of death (e.g., 01-Jan-1900): Product Use\/Medication Error Life-threatening Product Problem (e.g., defects\/malfunctions) Hospitalization (initial or prolonged) Required Intervention to Prevent Permanent Impairment\/Damage Problem with Different Manufacturer of Same Medicine Other Serious or Important Medical Events Congenital Anomaly\/Birth Defects Disability or Permanent Damage 3. Date of Event (e.g., 01-Jan-1900) 4. Date of this Report (e.g., 01-Jan-1900) 5. Describe Event, Problem or Product Use\/Medication Error Characters Remaining (max. 4,000): (field continues on next page) Submission of a report does not constitute an admission that medical personnel or the product caused or contributed to the event. * Please see instructions Form FDA-3500 (11\/22) Page 1 of 6 PSC Publishing Services (301) 443-6740 EF 6. Relevant Test\/Laboratory Data Date (e.g., 01-Jan-1900) Relevant Test\/Laboratory Data Additional comments Date (e.g., 01-Jan-1900) Characters Remaining (max. 2,000): 7. Other Relevant History, Including Preexisting Medical Conditions (e.g., allergies, pregnancy, tobacco product use, liver\/kidney Characters Remaining (max. 2,000): problems, etc.) Form FDA-3500 (11\/22) Page 2 of 6 (continued on next page) C. PRODUCT AVAILABILITY 1. Product Available for Evaluation? (Do not send product to FDA) No Yes Returned to Manufacturer on (e.g., 01-Jan-1900) 2. Do you have a picture of the product? (Check if you are including a picture) Yes D. SUSPECT PRODUCTS SUSPECT PRODUCT #1 This report involves: Cosmetic Dietary supplement Food\/medical food Other 1. Name, Strength, Manufacturer\/Compounder (from product label). Strength Product Name NDC # or Unique ID Unit Manufacturer\/ Compounder Name 2. Dose or Amount Unit Lot # Frequency Route Other Frequency Other Route 3. Treament Dates\/Therapy Dates (give best estimate of length of treatment (start\/stop) or date of dose reduction.) Unit OR Duration Therapy started on Therapy stopped on Dose reduced on (e.g., 01-Jan-1900) (e.g., 01-Jan-1900) (e.g., 01-Jan-1900) Is therapy still on-going? Yes No 4. Diagnosis for use (indication) 5. Product Type (check all that apply) 6. Expiration Date (e.g., 01-Jan-1900) OTC Compounded 7. Event Abated after use Stopped or Dose Reduced? Yes No This report involves: 8. Event Reappeared after Reintroduction? Yes Doesn\u2019t apply SUSPECT PRODUCT #2 Cosmetic Generic Biosimilar Dietary supplement No Doesn\u2019t apply Food\/medical food Other 1. Name, Strength, Manufacturer\/Compounder (from product label). Strength Product Name NDC # or Unique ID Unit Manufacturer\/ Compounder Name 2. Dose or Amount Unit Lot # Frequency Route Other Frequency Other Route 3. Treament Dates\/Therapy Dates (give best estimate of length of treatment (start\/stop) or date of dose reduction.) Unit OR Duration Therapy started on Therapy stopped on Dose reduced on (e.g., 01-Jan-1900) (e.g., 01-Jan-1900) (e.g., 01-Jan-1900) Is therapy still on-going? Yes No 4. Diagnosis for use (indication) 5. Product Type (check all that apply) 6. Expiration Date (e.g., 01-Jan-1900) OTC Compounded 7. Event Abated after use Stopped or Dose Reduced? Yes Form FDA-3500 No Doesn\u2019t apply (11\/22) Generic Biosimilar 8. Event Reappeared after Reintroduction? Yes Page 3 of 6 No Doesn\u2019t apply (continued on next page) E. SUSPECT MEDICAL DEVICE 1. Brand Name 2a. Common Device Name 2b. Procode 3. Manufacurer Name, City and State 4. Model # Lot # Catalog # Expiration Date (e.g., 01-Jan-1900) Serial # Unique Device Identifier (UDI) # 5. Operator of device Health Professional Patient\/Consumer Other 6a. If Implanted, Give Date (e.g., 01-Jan-1900) 6b. If Explanted, Give Date (e.g., 01-Jan-1900) 7a. Is this a single-use device that was reprocessed and reused on a patient? No Yes 7b. If Yes to Item 7a, Enter Name, Address of Reprocessor 8. Was this device ever serviced by a third-party servicer? Yes No Unknown F. OTHER (CONCOMITANT) MEDICAL PRODUCTS 1. Product names and therapy dates (Exclude treatment of event) Product Name Therapy Start Date (e.g., 01-Jan-1900) Therapy End Date (e.g., 01-Jan-1900) 1. 2. 3. 4. 5. 6. 7. 8. 9. 10. Form FDA-3500 (11\/22) Page 4 of 6 (continued on next page) G. REPORTER (See confidentiality section on next page) 1. Name and Address First Name Last Name Address City State\/Province\/Region ZIP\/Postal Code Country Phone # Email 2. Health Professional? 3. Occupation Yes 4. Also Reported to: Manufacturer\/Compounder No User Facility Distributor\/Importer 5. If you do NOT want your identity disclosed to the manufacturer, please mark this box: ADVICE ABOUT VOLUNTARY REPORTING Detailed instructions available at: https:\/\/www.fda.gov\/safety\/medwatch-forms-fda-safety-reporting\/instructions-completing-form-fda-3500<\/a> Report even if: Report adverse events, product problems or product use errors with: \u2022 You\u2019re not certain the product caused the event \u2022 Medications(drugs or biologics) \u2022 You don\u2019t have all the details \u2022 Medical devices (including diabetes glucose-test kit, \u2022 Just fill in the sections that apply to your report hearing aids, breast pumps, and many more) How to report: \u2022 Combination products(medication & medical devices) \u2022 Use section D for all products except medical devices \u2022 Blood transfusions, gene therapies, and human cells \u2022 Attach additional pages if needed and tissue transplants (for example, tendons, bone, \u2022 Use a separate form for each patient and corneas) \u2022 Report either to FDA or the manufacturer (or both) \u2022 Special nutritional products(dietary supplements, How to submit report: medical foods, infant formulas) \u2022 To report by phone, call toll-free: 1-800-FDA (332)\u2022 Cosmetics (such as moisturizers, makeup, shampoos 1088 and conditioners, face and body washes, deodorants, \u2022 To fax report: 1-800-FDA (332)-0178 nail care products, hair dyes and relaxers, and \u2022 To report online: www.fda.gov\/medwatch\/report.htm tattoos) \u2022 Food (including beverages and ingredients added to If your report involves a serious adverse event with a foods) device and it occurred in a facility outside a doctor\u2019s Report product problems \u2013 quality, performance or office, that facility may be legally required to report to safety concerns such as: FDA and\/or the manufacturer. Please notify the person \u2022 Suspected counterfeit product in that facility who would handle such reporting. \u2022 Suspected contamination Where to submit adverse events related to the following \u2022 Questionable stability products: \u2022 Defective components \u2022 If your report involves an animal drug, device, pet \u2022 Poor packaging or labeling food and livestock feed problems, go to \u2022 Therapeutic failures (product didn\u2019t work) http:\/\/www.fda.gov\/v<\/a>etproductreporting Report SERIOUS adverse events. An event is serious \u2022 If your report involves a health problem or a product when the patient outcome is: problem with a tobacco product, go to \u2022 Death https:\/\/www.safetyreporting.hhs.gov<\/a> or call \u2022 Life-threatening 1-877-287-1373 to report. \u2022 Hospitalization (initial or prolonged) \u2022 If your report involves an adverse event with a \u2022 Disability or permanent damage vaccine, go to http:\/\/vaers.hhs.gov<\/a> to report or call \u2022 Congenital anomaly\/birth defect 1-800-822-7967. \u2022 Required intervention to prevent permanent impairment or damage \u2022 Other serious (important medical events) Form FDA-3500 (11\/22) Page 5 of 6 Confidentiality: The patient\u2019s identity is held in strict confidence by FDA and protected to the fullest extent of the law. The reporter\u2019s identity, including the identity of a self-reporter, may be shared with the manufacturer unless requested otherwise. Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff PRAStaff@fda.hhs.gov The information in this box applies only to requirements of the Paperwork Reduction Act of 1995 Please DO NOT RETURN this form to the PRA Staff e-mail above. The burden time for this collection of information has been estimated to average 40 minutes per response, including the time to review instructions, search existing data sources, gather and maintain the data needed, and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to: Form FDA-3500 (11\/22) OMB statement: \u201cAn agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB control number.\u201d U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES Page 6 of 6<\/p>\nA Sample Answer For the Assignment: HIM 2433 MDC Reporting Adverse Reaction Question<\/strong><\/h2>\nTitle: <\/strong> HIM 2433 MDC Reporting Adverse Reaction Question<\/strong><\/h2>\n\n- Grid View<\/a><\/u><\/strong><\/li>\n<\/ul>\n
\n\n\n\u00a0<\/strong><\/td>\nExcellent<\/strong><\/td>\nGood<\/strong><\/td>\nFair<\/strong><\/td>\nPoor<\/strong><\/td>\n<\/tr>\n<\/thead>\n\n\nMain Postinga<\/strong><\/td>\n45\u00a0(45%)\u00a0– 50\u00a0(50%)<\/p>\nAnswers all parts of the discussion question(s) expectations with reflective critical analysis and synthesis of knowledge gained from the course readings for the module and current credible sources.<\/p>\n
<\/p>\n
Supported by at least three current, credible sources.<\/p>\n
<\/p>\n
Written clearly and concisely with no grammatical or spelling errors and fully adheres to current APA manual writing rules and style.<\/td>\n
40\u00a0(40%)\u00a0– 44\u00a0(44%)<\/p>\nResponds to the discussion question(s) and is reflective with critical analysis and synthesis of knowledge gained from the course readings for the module.<\/p>\n
<\/p>\n
At least 75% of post has exceptional depth and breadth.<\/p>\n
<\/p>\n
Supported by at least three credible sources.<\/p>\n
<\/p>\n
Written clearly and concisely with one or no grammatical or spelling errors and fully adheres to current APA manual writing rules and style.<\/td>\n
35\u00a0(35%)\u00a0– 39\u00a0(39%)<\/p>\nResponds to some of the discussion question(s).<\/p>\n
<\/p>\n
One or two criteria are not addressed or are superficially addressed.<\/p>\n
<\/p>\n
Is somewhat lacking reflection and critical analysis and synthesis.<\/p>\n
<\/p>\n
Somewhat represents knowledge gained from the course readings for the module.<\/p>\n
<\/p>\n
Post is cited with two credible sources.<\/p>\n
<\/p>\n
Written somewhat concisely; may contain more than two spelling or grammatical errors.<\/p>\n
<\/p>\n
Contains some APA formatting errors.<\/td>\n
0\u00a0(0%)\u00a0– 34\u00a0(34%)<\/p>\nDoes not respond to the discussion question(s) adequately.<\/p>\n
<\/p>\n
Lacks depth or superficially addresses criteria.<\/p>\n
<\/p>\n
Lacks reflection and critical analysis and synthesis.<\/p>\n
<\/p>\n
Does not represent knowledge gained from the course readings for the module.<\/p>\n
<\/p>\n
Contains only one or no credible sources.<\/p>\n
<\/p>\n
Not written clearly or concisely.<\/p>\n
<\/p>\n
Contains more than two spelling or grammatical errors.<\/p>\n
<\/p>\n
Does not adhere to current APA manual writing rules and style.<\/td>\n<\/tr>\n
\nMain Post: Timeliness<\/strong><\/td>\n10\u00a0(10%)\u00a0– 10\u00a0(10%)<\/p>\nPosts main post by day 3.<\/td>\n
0\u00a0(0%)\u00a0– 0\u00a0(0%)<\/td>\n 0\u00a0(0%)\u00a0– 0\u00a0(0%)<\/td>\n 0\u00a0(0%)\u00a0– 0\u00a0(0%)<\/p>\nDoes not post by day 3.<\/td>\n<\/tr>\n
\nFirst Response<\/strong><\/td>\n17\u00a0(17%)\u00a0– 18\u00a0(18%)<\/p>\nResponse exhibits synthesis, critical thinking, and application to practice settings.<\/p>\n
<\/p>\n
Responds fully to questions posed by faculty.<\/p>\n
<\/p>\n
Provides clear, concise opinions and ideas that are supported by at least two scholarly sources.<\/p>\n
<\/p>\n
Demonstrates synthesis and understanding of learning objectives.<\/p>\n
<\/p>\n
Communication is professional and respectful to colleagues.<\/p>\n
<\/p>\n
Responses to faculty questions are fully answered, if posed.<\/p>\n
<\/p>\n
Response is effectively written in standard, edited English.<\/td>\n
15\u00a0(15%)\u00a0– 16\u00a0(16%)<\/p>\nResponse exhibits critical thinking and application to practice settings.<\/p>\n
<\/p>\n
Communication is professional and respectful to colleagues.<\/p>\n
<\/p>\n
Responses to faculty questions are answered, if posed.<\/p>\n
<\/p>\n
Provides clear, concise opinions and ideas that are supported by two or more credible sources.<\/p>\n
<\/p>\n
Response is effectively written in standard, edited English.<\/td>\n
13\u00a0(13%)\u00a0– 14\u00a0(14%)<\/p>\nResponse is on topic and may have some depth.<\/p>\n
<\/p>\n
Responses posted in the discussion may lack effective professional communication.<\/p>\n
<\/p>\n
Responses to faculty questions are somewhat answered, if posed.<\/p>\n
<\/p>\n
Response may lack clear, concise opinions and ideas, and a few or no credible sources are cited.<\/td>\n
0\u00a0(0%)\u00a0– 12\u00a0(12%)<\/p>\nResponse may not be on topic and lacks depth.<\/p>\n
<\/p>\n
Responses posted in the discussion lack effective professional communication.<\/p>\n
<\/p>\n
Responses to faculty questions are missing.<\/p>\n
<\/p>\n
No credible sources are cited.<\/td>\n<\/tr>\n
\nSecond Response<\/strong><\/td>\n16\u00a0(16%)\u00a0– 17\u00a0(17%)<\/p>\nResponse exhibits synthesis, critical thinking, and application to practice settings.<\/p>\n
<\/p>\n
Responds fully to questions posed by faculty.<\/p>\n
<\/p>\n
Provides clear, concise opinions and ideas that are supported by at least two scholarly sources.<\/p>\n
<\/p>\n
Demonstrates synthesis and understanding of learning objectives.<\/p>\n
<\/p>\n
Communication is professional and respectful to colleagues.<\/p>\n
<\/p>\n
Responses to faculty questions are fully answered, if posed.<\/p>\n
<\/p>\n
Response is effectively written in standard, edited English.<\/td>\n
14\u00a0(14%)\u00a0– 15\u00a0(15%)<\/p>\nResponse exhibits critical thinking and application to practice settings.<\/p>\n
<\/p>\n
Communication is professional and respectful to colleagues.<\/p>\n
<\/p>\n
Responses to faculty questions are answered, if posed.<\/p>\n
<\/p>\n
Provides clear, concise opinions and ideas that are supported by two or more credible sources.<\/p>\n
<\/p>\n
Response is effectively written in standard, edited English.<\/td>\n
12\u00a0(12%)\u00a0– 13\u00a0(13%)<\/p>\nResponse is on topic and may have some depth.<\/p>\n
<\/p>\n
Responses posted in the discussion may lack effective professional communication.<\/p>\n
<\/p>\n
Responses to faculty questions are somewhat answered, if posed.<\/p>\n
<\/p>\n
Response may lack clear, concise opinions and ideas, and a few or no credible sources are cited.<\/td>\n
0\u00a0(0%)\u00a0– 11\u00a0(11%)<\/p>\nResponse may not be on topic and lacks depth.<\/p>\n
<\/p>\n
Responses posted in the discussion lack effective professional communication.<\/p>\n
<\/p>\n
Responses to faculty questions are missing.<\/p>\n
<\/p>\n
No credible sources are cited.<\/td>\n<\/tr>\n
\nParticipation<\/strong><\/td>\n5\u00a0(5%)\u00a0– 5\u00a0(5%)<\/p>\nMeets requirements for participation by posting on three different days.<\/td>\n
0\u00a0(0%)\u00a0– 0\u00a0(0%)<\/td>\n 0\u00a0(0%)\u00a0– 0\u00a0(0%)<\/td>\n 0\u00a0(0%)\u00a0– 0\u00a0(0%)<\/p>\nDoes not meet requirements for participation by posting on 3 different days.<\/td>\n<\/tr>\n
\nTotal Points: 100<\/td>\n <\/td>\n<\/tr>\n \n<\/td>\n <\/td>\n <\/td>\n <\/td>\n <\/td>\n <\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n <\/p>\n
<\/p>\n","protected":false},"excerpt":{"rendered":"
HIM 2433 MDC Reporting Adverse Reaction Question Sample Answer for HIM 2433 MDC Reporting Adverse Reaction Question Included After Question Description Read the instructions associated with the form for adverse reactions. You will note that the form indicates that the patient had an adverse reaction to a drug. Your job is to review the health […]<\/p>\n","protected":false},"author":11,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-36225","post","type-post","status-publish","format-standard","hentry","category-nursing-papers"],"blocksy_meta":{"styles_descriptor":{"styles":{"desktop":"","tablet":"","mobile":""},"google_fonts":[],"version":6}},"yoast_head":"\n
HIM 2433 MDC Reporting Adverse Reaction Question - Nursing Assignment Crackers<\/title>\n<meta name=\"description\" content=\"HIM 2433 MDC Reporting Adverse Reaction Question-urinary tract infection\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/nursingassignmentcrackers.com\/him-2433-mdc-reporting-adverse-reaction-question\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"HIM 2433 MDC Reporting Adverse Reaction Question - Nursing Assignment Crackers\" \/>\n<meta property=\"og:description\" content=\"HIM 2433 MDC Reporting Adverse Reaction Question-urinary tract infection\" \/>\n<meta property=\"og:url\" content=\"https:\/\/nursingassignmentcrackers.com\/him-2433-mdc-reporting-adverse-reaction-question\/\" \/>\n<meta property=\"og:site_name\" content=\"Nursing Assignment Crackers\" \/>\n<meta property=\"article:published_time\" content=\"2023-03-15T11:31:45+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-03-25T09:58:35+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/nursingassignmentcrackers.com\/wp-content\/uploads\/2023\/03\/HIM-2433-MDC-Reporting-Adverse-Reaction-Question-300x138.png\" \/>\n<meta name=\"author\" content=\"Saraphine\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Saraphine\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"13 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/nursingassignmentcrackers.com\/him-2433-mdc-reporting-adverse-reaction-question\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/nursingassignmentcrackers.com\/him-2433-mdc-reporting-adverse-reaction-question\/\"},\"author\":{\"name\":\"Saraphine\",\"@id\":\"https:\/\/nursingassignmentcrackers.com\/#\/schema\/person\/eb5212513ef8667ef7a4ce51a5333807\"},\"headline\":\"HIM 2433 MDC Reporting Adverse Reaction Question\",\"datePublished\":\"2023-03-15T11:31:45+00:00\",\"dateModified\":\"2024-03-25T09:58:35+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/nursingassignmentcrackers.com\/him-2433-mdc-reporting-adverse-reaction-question\/\"},\"wordCount\":2733,\"publisher\":{\"@id\":\"https:\/\/nursingassignmentcrackers.com\/#organization\"},\"image\":{\"@id\":\"https:\/\/nursingassignmentcrackers.com\/him-2433-mdc-reporting-adverse-reaction-question\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/nursingassignmentcrackers.com\/wp-content\/uploads\/2023\/03\/HIM-2433-MDC-Reporting-Adverse-Reaction-Question-300x138.png\",\"articleSection\":[\"Nursing Papers\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/nursingassignmentcrackers.com\/him-2433-mdc-reporting-adverse-reaction-question\/\",\"url\":\"https:\/\/nursingassignmentcrackers.com\/him-2433-mdc-reporting-adverse-reaction-question\/\",\"name\":\"HIM 2433 MDC Reporting Adverse Reaction Question - Nursing Assignment Crackers\",\"isPartOf\":{\"@id\":\"https:\/\/nursingassignmentcrackers.com\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/nursingassignmentcrackers.com\/him-2433-mdc-reporting-adverse-reaction-question\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/nursingassignmentcrackers.com\/him-2433-mdc-reporting-adverse-reaction-question\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/nursingassignmentcrackers.com\/wp-content\/uploads\/2023\/03\/HIM-2433-MDC-Reporting-Adverse-Reaction-Question-300x138.png\",\"datePublished\":\"2023-03-15T11:31:45+00:00\",\"dateModified\":\"2024-03-25T09:58:35+00:00\",\"description\":\"HIM 2433 MDC Reporting Adverse Reaction Question-urinary tract infection\",\"breadcrumb\":{\"@id\":\"https:\/\/nursingassignmentcrackers.com\/him-2433-mdc-reporting-adverse-reaction-question\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/nursingassignmentcrackers.com\/him-2433-mdc-reporting-adverse-reaction-question\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/nursingassignmentcrackers.com\/him-2433-mdc-reporting-adverse-reaction-question\/#primaryimage\",\"url\":\"https:\/\/nursingassignmentcrackers.com\/wp-content\/uploads\/2023\/03\/HIM-2433-MDC-Reporting-Adverse-Reaction-Question.png\",\"contentUrl\":\"https:\/\/nursingassignmentcrackers.com\/wp-content\/uploads\/2023\/03\/HIM-2433-MDC-Reporting-Adverse-Reaction-Question.png\",\"width\":984,\"height\":453,\"caption\":\"HIM 2433 MDC Reporting Adverse Reaction Question\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/nursingassignmentcrackers.com\/him-2433-mdc-reporting-adverse-reaction-question\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/nursingassignmentcrackers.com\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"HIM 2433 MDC Reporting Adverse Reaction Question\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/nursingassignmentcrackers.com\/#website\",\"url\":\"https:\/\/nursingassignmentcrackers.com\/\",\"name\":\"Nursing Assignment Crackers\",\"description\":\"Professional Nursing Assignment Writing Service\",\"publisher\":{\"@id\":\"https:\/\/nursingassignmentcrackers.com\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/nursingassignmentcrackers.com\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/nursingassignmentcrackers.com\/#organization\",\"name\":\"Nursing Assignment Crackers\",\"url\":\"https:\/\/nursingassignmentcrackers.com\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/nursingassignmentcrackers.com\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/nursingassignmentcrackers.com\/wp-content\/uploads\/2023\/03\/nurse-2.png\",\"contentUrl\":\"https:\/\/nursingassignmentcrackers.com\/wp-content\/uploads\/2023\/03\/nurse-2.png\",\"width\":512,\"height\":512,\"caption\":\"Nursing Assignment Crackers\"},\"image\":{\"@id\":\"https:\/\/nursingassignmentcrackers.com\/#\/schema\/logo\/image\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\/\/nursingassignmentcrackers.com\/#\/schema\/person\/eb5212513ef8667ef7a4ce51a5333807\",\"name\":\"Saraphine\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/nursingassignmentcrackers.com\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/3b72d7a762dce500483486826fc831bc?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/3b72d7a762dce500483486826fc831bc?s=96&d=mm&r=g\",\"caption\":\"Saraphine\"},\"url\":\"https:\/\/nursingassignmentcrackers.com\/author\/saraphine\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"HIM 2433 MDC Reporting Adverse Reaction Question - Nursing Assignment Crackers","description":"HIM 2433 MDC Reporting Adverse Reaction Question-urinary tract infection","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/nursingassignmentcrackers.com\/him-2433-mdc-reporting-adverse-reaction-question\/","og_locale":"en_US","og_type":"article","og_title":"HIM 2433 MDC Reporting Adverse Reaction Question - Nursing Assignment Crackers","og_description":"HIM 2433 MDC Reporting Adverse Reaction Question-urinary tract infection","og_url":"https:\/\/nursingassignmentcrackers.com\/him-2433-mdc-reporting-adverse-reaction-question\/","og_site_name":"Nursing Assignment Crackers","article_published_time":"2023-03-15T11:31:45+00:00","article_modified_time":"2024-03-25T09:58:35+00:00","og_image":[{"url":"https:\/\/nursingassignmentcrackers.com\/wp-content\/uploads\/2023\/03\/HIM-2433-MDC-Reporting-Adverse-Reaction-Question-300x138.png"}],"author":"Saraphine","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Saraphine","Est. reading time":"13 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/nursingassignmentcrackers.com\/him-2433-mdc-reporting-adverse-reaction-question\/#article","isPartOf":{"@id":"https:\/\/nursingassignmentcrackers.com\/him-2433-mdc-reporting-adverse-reaction-question\/"},"author":{"name":"Saraphine","@id":"https:\/\/nursingassignmentcrackers.com\/#\/schema\/person\/eb5212513ef8667ef7a4ce51a5333807"},"headline":"HIM 2433 MDC Reporting Adverse Reaction Question","datePublished":"2023-03-15T11:31:45+00:00","dateModified":"2024-03-25T09:58:35+00:00","mainEntityOfPage":{"@id":"https:\/\/nursingassignmentcrackers.com\/him-2433-mdc-reporting-adverse-reaction-question\/"},"wordCount":2733,"publisher":{"@id":"https:\/\/nursingassignmentcrackers.com\/#organization"},"image":{"@id":"https:\/\/nursingassignmentcrackers.com\/him-2433-mdc-reporting-adverse-reaction-question\/#primaryimage"},"thumbnailUrl":"https:\/\/nursingassignmentcrackers.com\/wp-content\/uploads\/2023\/03\/HIM-2433-MDC-Reporting-Adverse-Reaction-Question-300x138.png","articleSection":["Nursing Papers"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/nursingassignmentcrackers.com\/him-2433-mdc-reporting-adverse-reaction-question\/","url":"https:\/\/nursingassignmentcrackers.com\/him-2433-mdc-reporting-adverse-reaction-question\/","name":"HIM 2433 MDC Reporting Adverse Reaction Question - Nursing Assignment Crackers","isPartOf":{"@id":"https:\/\/nursingassignmentcrackers.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/nursingassignmentcrackers.com\/him-2433-mdc-reporting-adverse-reaction-question\/#primaryimage"},"image":{"@id":"https:\/\/nursingassignmentcrackers.com\/him-2433-mdc-reporting-adverse-reaction-question\/#primaryimage"},"thumbnailUrl":"https:\/\/nursingassignmentcrackers.com\/wp-content\/uploads\/2023\/03\/HIM-2433-MDC-Reporting-Adverse-Reaction-Question-300x138.png","datePublished":"2023-03-15T11:31:45+00:00","dateModified":"2024-03-25T09:58:35+00:00","description":"HIM 2433 MDC Reporting Adverse Reaction Question-urinary tract infection","breadcrumb":{"@id":"https:\/\/nursingassignmentcrackers.com\/him-2433-mdc-reporting-adverse-reaction-question\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/nursingassignmentcrackers.com\/him-2433-mdc-reporting-adverse-reaction-question\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/nursingassignmentcrackers.com\/him-2433-mdc-reporting-adverse-reaction-question\/#primaryimage","url":"https:\/\/nursingassignmentcrackers.com\/wp-content\/uploads\/2023\/03\/HIM-2433-MDC-Reporting-Adverse-Reaction-Question.png","contentUrl":"https:\/\/nursingassignmentcrackers.com\/wp-content\/uploads\/2023\/03\/HIM-2433-MDC-Reporting-Adverse-Reaction-Question.png","width":984,"height":453,"caption":"HIM 2433 MDC Reporting Adverse Reaction Question"},{"@type":"BreadcrumbList","@id":"https:\/\/nursingassignmentcrackers.com\/him-2433-mdc-reporting-adverse-reaction-question\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/nursingassignmentcrackers.com\/"},{"@type":"ListItem","position":2,"name":"HIM 2433 MDC Reporting Adverse Reaction Question"}]},{"@type":"WebSite","@id":"https:\/\/nursingassignmentcrackers.com\/#website","url":"https:\/\/nursingassignmentcrackers.com\/","name":"Nursing Assignment Crackers","description":"Professional Nursing Assignment Writing Service","publisher":{"@id":"https:\/\/nursingassignmentcrackers.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/nursingassignmentcrackers.com\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/nursingassignmentcrackers.com\/#organization","name":"Nursing Assignment Crackers","url":"https:\/\/nursingassignmentcrackers.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/nursingassignmentcrackers.com\/#\/schema\/logo\/image\/","url":"https:\/\/nursingassignmentcrackers.com\/wp-content\/uploads\/2023\/03\/nurse-2.png","contentUrl":"https:\/\/nursingassignmentcrackers.com\/wp-content\/uploads\/2023\/03\/nurse-2.png","width":512,"height":512,"caption":"Nursing Assignment Crackers"},"image":{"@id":"https:\/\/nursingassignmentcrackers.com\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/nursingassignmentcrackers.com\/#\/schema\/person\/eb5212513ef8667ef7a4ce51a5333807","name":"Saraphine","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/nursingassignmentcrackers.com\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/3b72d7a762dce500483486826fc831bc?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/3b72d7a762dce500483486826fc831bc?s=96&d=mm&r=g","caption":"Saraphine"},"url":"https:\/\/nursingassignmentcrackers.com\/author\/saraphine\/"}]}},"_links":{"self":[{"href":"https:\/\/nursingassignmentcrackers.com\/wp-json\/wp\/v2\/posts\/36225","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/nursingassignmentcrackers.com\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/nursingassignmentcrackers.com\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/nursingassignmentcrackers.com\/wp-json\/wp\/v2\/users\/11"}],"replies":[{"embeddable":true,"href":"https:\/\/nursingassignmentcrackers.com\/wp-json\/wp\/v2\/comments?post=36225"}],"version-history":[{"count":6,"href":"https:\/\/nursingassignmentcrackers.com\/wp-json\/wp\/v2\/posts\/36225\/revisions"}],"predecessor-version":[{"id":139898,"href":"https:\/\/nursingassignmentcrackers.com\/wp-json\/wp\/v2\/posts\/36225\/revisions\/139898"}],"wp:attachment":[{"href":"https:\/\/nursingassignmentcrackers.com\/wp-json\/wp\/v2\/media?parent=36225"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/nursingassignmentcrackers.com\/wp-json\/wp\/v2\/categories?post=36225"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/nursingassignmentcrackers.com\/wp-json\/wp\/v2\/tags?post=36225"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}
Read the instructions associated with the form for adverse reactions. You will note that the form indicates that the patient had an adverse reaction to a drug.<\/p>\n
Your job is to review the health record document, determine, and report the adverse reaction. Pay close attention to what is required of D1 & D4. Put your name in textbox “G” as the reporter.<\/p>\n
DISCHARGE<\/span>\u00a0SUMMARY<\/span> Click here to ORDER an A++ paper from our Verified MASTERS and DOCTORATE WRITERS:HIM 2433 MDC Reporting Adverse Reaction Question<\/strong><\/a><\/span><\/p>\n Discharge Medications<\/span> Reset Form DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration The FDA Safety Information and Adverse Event Reporting Program Form FDA 3500 Form Approved: OMB No. 0910-0291, Expires: 06-30-2025 See PRA statement on page 6. FDA USE ONLY Triage unit sequence # FDA Rec. Date For VOLUNTARY reporting of adverse events, product problems and product use\/medication errors Note: For date prompts of \u201cdd-mmm-yyyy\u201d please use 2-digit day, 3-letter month abbreviation, and 4-digit year; for example, 01-Jan-1900. A. PATIENT INFORMATION 1. Patient Identifier (In confidence) 3a. Sex: Enter the patient\u2019s sex at birth (the sex that a person has or was assigned to at birth). Male Undifferentiated Female Decline to answer 4. Weight 2. Age or Date of Birth (e.g., 01-Jan-1900) Year(s) Week(s) Month(s) Day(s) 3b. Gender: Enter the patient\u2019s current gender (how the patient thinks of themself). lb 5. Ethnicity (Check one) Hispanic\/Latino kg Not Hispanic\/Latino Cisgender man\/boy (gender corresponds with birth sex) Transgender woman\/trans woman\/ male-to-female (MTF) Cisgender woman\/girl (gender corresponds with birth sex) Other gender category; please specify: Transgender man\/trans man\/ female-to-male (FTM) Decline to answer 6. Race (check all that apply) American Indian\/Alaska Native Asian Black or African American Native Hawaiian\/ Other Pacific Islander White B. ADVERSE EVENT, PRODUCT PROBLEM 1. Type of Report (check all that apply) 2. Outcome Attributed to Adverse Event (check all that apply) Adverse Event Death \u2013 Date of death (e.g., 01-Jan-1900): Product Use\/Medication Error Life-threatening Product Problem (e.g., defects\/malfunctions) Hospitalization (initial or prolonged) Required Intervention to Prevent Permanent Impairment\/Damage Problem with Different Manufacturer of Same Medicine Other Serious or Important Medical Events Congenital Anomaly\/Birth Defects Disability or Permanent Damage 3. Date of Event (e.g., 01-Jan-1900) 4. Date of this Report (e.g., 01-Jan-1900) 5. Describe Event, Problem or Product Use\/Medication Error Characters Remaining (max. 4,000): (field continues on next page) Submission of a report does not constitute an admission that medical personnel or the product caused or contributed to the event. * Please see instructions Form FDA-3500 (11\/22) Page 1 of 6 PSC Publishing Services (301) 443-6740 EF 6. Relevant Test\/Laboratory Data Date (e.g., 01-Jan-1900) Relevant Test\/Laboratory Data Additional comments Date (e.g., 01-Jan-1900) Characters Remaining (max. 2,000): 7. Other Relevant History, Including Preexisting Medical Conditions (e.g., allergies, pregnancy, tobacco product use, liver\/kidney Characters Remaining (max. 2,000): problems, etc.) Form FDA-3500 (11\/22) Page 2 of 6 (continued on next page) C. PRODUCT AVAILABILITY 1. Product Available for Evaluation? (Do not send product to FDA) No Yes Returned to Manufacturer on (e.g., 01-Jan-1900) 2. Do you have a picture of the product? (Check if you are including a picture) Yes D. SUSPECT PRODUCTS SUSPECT PRODUCT #1 This report involves: Cosmetic Dietary supplement Food\/medical food Other 1. Name, Strength, Manufacturer\/Compounder (from product label). Strength Product Name NDC # or Unique ID Unit Manufacturer\/ Compounder Name 2. Dose or Amount Unit Lot # Frequency Route Other Frequency Other Route 3. Treament Dates\/Therapy Dates (give best estimate of length of treatment (start\/stop) or date of dose reduction.) Unit OR Duration Therapy started on Therapy stopped on Dose reduced on (e.g., 01-Jan-1900) (e.g., 01-Jan-1900) (e.g., 01-Jan-1900) Is therapy still on-going? Yes No 4. Diagnosis for use (indication) 5. Product Type (check all that apply) 6. Expiration Date (e.g., 01-Jan-1900) OTC Compounded 7. Event Abated after use Stopped or Dose Reduced? Yes No This report involves: 8. Event Reappeared after Reintroduction? Yes Doesn\u2019t apply SUSPECT PRODUCT #2 Cosmetic Generic Biosimilar Dietary supplement No Doesn\u2019t apply Food\/medical food Other 1. Name, Strength, Manufacturer\/Compounder (from product label). Strength Product Name NDC # or Unique ID Unit Manufacturer\/ Compounder Name 2. Dose or Amount Unit Lot # Frequency Route Other Frequency Other Route 3. Treament Dates\/Therapy Dates (give best estimate of length of treatment (start\/stop) or date of dose reduction.) Unit OR Duration Therapy started on Therapy stopped on Dose reduced on (e.g., 01-Jan-1900) (e.g., 01-Jan-1900) (e.g., 01-Jan-1900) Is therapy still on-going? Yes No 4. Diagnosis for use (indication) 5. Product Type (check all that apply) 6. Expiration Date (e.g., 01-Jan-1900) OTC Compounded 7. Event Abated after use Stopped or Dose Reduced? Yes Form FDA-3500 No Doesn\u2019t apply (11\/22) Generic Biosimilar 8. Event Reappeared after Reintroduction? Yes Page 3 of 6 No Doesn\u2019t apply (continued on next page) E. SUSPECT MEDICAL DEVICE 1. Brand Name 2a. Common Device Name 2b. Procode 3. Manufacurer Name, City and State 4. Model # Lot # Catalog # Expiration Date (e.g., 01-Jan-1900) Serial # Unique Device Identifier (UDI) # 5. Operator of device Health Professional Patient\/Consumer Other 6a. If Implanted, Give Date (e.g., 01-Jan-1900) 6b. If Explanted, Give Date (e.g., 01-Jan-1900) 7a. Is this a single-use device that was reprocessed and reused on a patient? No Yes 7b. If Yes to Item 7a, Enter Name, Address of Reprocessor 8. Was this device ever serviced by a third-party servicer? Yes No Unknown F. OTHER (CONCOMITANT) MEDICAL PRODUCTS 1. Product names and therapy dates (Exclude treatment of event) Product Name Therapy Start Date (e.g., 01-Jan-1900) Therapy End Date (e.g., 01-Jan-1900) 1. 2. 3. 4. 5. 6. 7. 8. 9. 10. Form FDA-3500 (11\/22) Page 4 of 6 (continued on next page) G. REPORTER (See confidentiality section on next page) 1. Name and Address First Name Last Name Address City State\/Province\/Region ZIP\/Postal Code Country Phone # Email 2. Health Professional? 3. Occupation Yes 4. Also Reported to: Manufacturer\/Compounder No User Facility Distributor\/Importer 5. If you do NOT want your identity disclosed to the manufacturer, please mark this box: ADVICE ABOUT VOLUNTARY REPORTING Detailed instructions available at: https:\/\/www.fda.gov\/safety\/medwatch-forms-fda-safety-reporting\/instructions-completing-form-fda-3500<\/a> Report even if: Report adverse events, product problems or product use errors with: \u2022 You\u2019re not certain the product caused the event \u2022 Medications(drugs or biologics) \u2022 You don\u2019t have all the details \u2022 Medical devices (including diabetes glucose-test kit, \u2022 Just fill in the sections that apply to your report hearing aids, breast pumps, and many more) How to report: \u2022 Combination products(medication & medical devices) \u2022 Use section D for all products except medical devices \u2022 Blood transfusions, gene therapies, and human cells \u2022 Attach additional pages if needed and tissue transplants (for example, tendons, bone, \u2022 Use a separate form for each patient and corneas) \u2022 Report either to FDA or the manufacturer (or both) \u2022 Special nutritional products(dietary supplements, How to submit report: medical foods, infant formulas) \u2022 To report by phone, call toll-free: 1-800-FDA (332)\u2022 Cosmetics (such as moisturizers, makeup, shampoos 1088 and conditioners, face and body washes, deodorants, \u2022 To fax report: 1-800-FDA (332)-0178 nail care products, hair dyes and relaxers, and \u2022 To report online: www.fda.gov\/medwatch\/report.htm tattoos) \u2022 Food (including beverages and ingredients added to If your report involves a serious adverse event with a foods) device and it occurred in a facility outside a doctor\u2019s Report product problems \u2013 quality, performance or office, that facility may be legally required to report to safety concerns such as: FDA and\/or the manufacturer. Please notify the person \u2022 Suspected counterfeit product in that facility who would handle such reporting. \u2022 Suspected contamination Where to submit adverse events related to the following \u2022 Questionable stability products: \u2022 Defective components \u2022 If your report involves an animal drug, device, pet \u2022 Poor packaging or labeling food and livestock feed problems, go to \u2022 Therapeutic failures (product didn\u2019t work) http:\/\/www.fda.gov\/v<\/a>etproductreporting Report SERIOUS adverse events. An event is serious \u2022 If your report involves a health problem or a product when the patient outcome is: problem with a tobacco product, go to \u2022 Death https:\/\/www.safetyreporting.hhs.gov<\/a> or call \u2022 Life-threatening 1-877-287-1373 to report. \u2022 Hospitalization (initial or prolonged) \u2022 If your report involves an adverse event with a \u2022 Disability or permanent damage vaccine, go to http:\/\/vaers.hhs.gov<\/a> to report or call \u2022 Congenital anomaly\/birth defect 1-800-822-7967. \u2022 Required intervention to prevent permanent impairment or damage \u2022 Other serious (important medical events) Form FDA-3500 (11\/22) Page 5 of 6 Confidentiality: The patient\u2019s identity is held in strict confidence by FDA and protected to the fullest extent of the law. The reporter\u2019s identity, including the identity of a self-reporter, may be shared with the manufacturer unless requested otherwise. Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff PRAStaff@fda.hhs.gov The information in this box applies only to requirements of the Paperwork Reduction Act of 1995 Please DO NOT RETURN this form to the PRA Staff e-mail above. The burden time for this collection of information has been estimated to average 40 minutes per response, including the time to review instructions, search existing data sources, gather and maintain the data needed, and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to: Form FDA-3500 (11\/22) OMB statement: \u201cAn agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB control number.\u201d U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES Page 6 of 6<\/p>\n Answers all parts of the discussion question(s) expectations with reflective critical analysis and synthesis of knowledge gained from the course readings for the module and current credible sources.<\/p>\n <\/p>\n Supported by at least three current, credible sources.<\/p>\n <\/p>\n Written clearly and concisely with no grammatical or spelling errors and fully adheres to current APA manual writing rules and style.<\/td>\n Responds to the discussion question(s) and is reflective with critical analysis and synthesis of knowledge gained from the course readings for the module.<\/p>\n <\/p>\n At least 75% of post has exceptional depth and breadth.<\/p>\n <\/p>\n Supported by at least three credible sources.<\/p>\n <\/p>\n Written clearly and concisely with one or no grammatical or spelling errors and fully adheres to current APA manual writing rules and style.<\/td>\n Responds to some of the discussion question(s).<\/p>\n <\/p>\n One or two criteria are not addressed or are superficially addressed.<\/p>\n <\/p>\n Is somewhat lacking reflection and critical analysis and synthesis.<\/p>\n <\/p>\n Somewhat represents knowledge gained from the course readings for the module.<\/p>\n <\/p>\n Post is cited with two credible sources.<\/p>\n <\/p>\n Written somewhat concisely; may contain more than two spelling or grammatical errors.<\/p>\n <\/p>\n Contains some APA formatting errors.<\/td>\n Does not respond to the discussion question(s) adequately.<\/p>\n <\/p>\n Lacks depth or superficially addresses criteria.<\/p>\n <\/p>\n Lacks reflection and critical analysis and synthesis.<\/p>\n <\/p>\n Does not represent knowledge gained from the course readings for the module.<\/p>\n <\/p>\n Contains only one or no credible sources.<\/p>\n <\/p>\n Not written clearly or concisely.<\/p>\n <\/p>\n Contains more than two spelling or grammatical errors.<\/p>\n <\/p>\n Does not adhere to current APA manual writing rules and style.<\/td>\n<\/tr>\n Posts main post by day 3.<\/td>\n Does not post by day 3.<\/td>\n<\/tr>\n Response exhibits synthesis, critical thinking, and application to practice settings.<\/p>\n <\/p>\n Responds fully to questions posed by faculty.<\/p>\n <\/p>\n Provides clear, concise opinions and ideas that are supported by at least two scholarly sources.<\/p>\n <\/p>\n Demonstrates synthesis and understanding of learning objectives.<\/p>\n <\/p>\n Communication is professional and respectful to colleagues.<\/p>\n <\/p>\n Responses to faculty questions are fully answered, if posed.<\/p>\n <\/p>\n Response is effectively written in standard, edited English.<\/td>\n Response exhibits critical thinking and application to practice settings.<\/p>\n <\/p>\n Communication is professional and respectful to colleagues.<\/p>\n <\/p>\n Responses to faculty questions are answered, if posed.<\/p>\n <\/p>\n Provides clear, concise opinions and ideas that are supported by two or more credible sources.<\/p>\n <\/p>\n Response is effectively written in standard, edited English.<\/td>\n Response is on topic and may have some depth.<\/p>\n <\/p>\n Responses posted in the discussion may lack effective professional communication.<\/p>\n <\/p>\n Responses to faculty questions are somewhat answered, if posed.<\/p>\n <\/p>\n Response may lack clear, concise opinions and ideas, and a few or no credible sources are cited.<\/td>\n Response may not be on topic and lacks depth.<\/p>\n <\/p>\n Responses posted in the discussion lack effective professional communication.<\/p>\n <\/p>\n Responses to faculty questions are missing.<\/p>\n <\/p>\n No credible sources are cited.<\/td>\n<\/tr>\n Response exhibits synthesis, critical thinking, and application to practice settings.<\/p>\n <\/p>\n Responds fully to questions posed by faculty.<\/p>\n <\/p>\n Provides clear, concise opinions and ideas that are supported by at least two scholarly sources.<\/p>\n <\/p>\n Demonstrates synthesis and understanding of learning objectives.<\/p>\n <\/p>\n Communication is professional and respectful to colleagues.<\/p>\n <\/p>\n Responses to faculty questions are fully answered, if posed.<\/p>\n <\/p>\n Response is effectively written in standard, edited English.<\/td>\n Response exhibits critical thinking and application to practice settings.<\/p>\n <\/p>\n Communication is professional and respectful to colleagues.<\/p>\n <\/p>\n Responses to faculty questions are answered, if posed.<\/p>\n <\/p>\n Provides clear, concise opinions and ideas that are supported by two or more credible sources.<\/p>\n <\/p>\n Response is effectively written in standard, edited English.<\/td>\n Response is on topic and may have some depth.<\/p>\n <\/p>\n Responses posted in the discussion may lack effective professional communication.<\/p>\n <\/p>\n Responses to faculty questions are somewhat answered, if posed.<\/p>\n <\/p>\n Response may lack clear, concise opinions and ideas, and a few or no credible sources are cited.<\/td>\n Response may not be on topic and lacks depth.<\/p>\n <\/p>\n Responses posted in the discussion lack effective professional communication.<\/p>\n <\/p>\n Responses to faculty questions are missing.<\/p>\n <\/p>\n No credible sources are cited.<\/td>\n<\/tr>\n Meets requirements for participation by posting on three different days.<\/td>\n Does not meet requirements for participation by posting on 3 different days.<\/td>\n<\/tr>\n <\/p>\n <\/p>\n","protected":false},"excerpt":{"rendered":" HIM 2433 MDC Reporting Adverse Reaction Question Sample Answer for HIM 2433 MDC Reporting Adverse Reaction Question Included After Question Description Read the instructions associated with the form for adverse reactions. You will note that the form indicates that the patient had an adverse reaction to a drug. Your job is to review the health […]<\/p>\n","protected":false},"author":11,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-36225","post","type-post","status-publish","format-standard","hentry","category-nursing-papers"],"blocksy_meta":{"styles_descriptor":{"styles":{"desktop":"","tablet":"","mobile":""},"google_fonts":[],"version":6}},"yoast_head":"\n
\nPATEL, SHERRY<\/span>\u00a0#0267852<\/span>
\nDATE OF<\/span>
\nADMISSION:<\/span>\u00a002\/26\/XX<\/span>\u00a0DATE OF DISCHARGE:<\/span>\u00a003\/01\/XX<\/span>
\nFINAL DIAGNOSES:<\/span>
\n1.<\/span>\u00a0Left femoral neck fracture<\/span>
\n2.<\/span>\u00a0Paroxysmal Atrial Fibrillation, converted<\/span>
\nto sinus rhythm<\/span>
\n3.<\/span>\u00a0Urinary tract infection<\/span>
\n4.<\/span>\u00a0Rash due to Bactrim<\/span>
\n5.<\/span>\u00a0Mild Dementia<\/span>
\n6.<\/span>\u00a0Hypertensive Heart Disease with<\/span>
\nhypercholestrolemia<\/span>
\n7.<\/span>\u00a0History of Strokes (Cerebrovascular<\/span>
\nAccidents [CVA])<\/span>
\nJustification of Admission<\/span>
\nThis 77<\/span>–<\/span>year<\/span>–<\/span>old female presented to the ER after falling at her beach<\/span>
\nhome.<\/span>\u00a0Upon examination, the patient complains of inability to walk and severe<\/span>
\nhip pain.<\/span>\u00a0H<\/span>er past medical history reveals multiple strokes with dementia<\/span>
\nresiduals and heart disease. X<\/span>–<\/span>rays revealed a femoral neck fracture.<\/span>\u00a0Patient<\/span>
\ncurrent medications include Coumadin, Diovan, OsCal, Magnesium chloride,<\/span>
\nMegace, Levothroid, Remeron, and Lipitor<\/span>.<\/span>
\nHospital Course<\/span>
\nThe patient was admitted and Dr. Black an Orthopedic surgeon was consulted.<\/span>
\nOn the evening of 02\/26, an open reduction and internal fixation repair was<\/span>
\nperformed on the left hip.<\/span>\u00a0During the surgery there was a great deal of bloo<\/span>d<\/span>
\nloss that was replaced with three units of packed cells. The patient transfused<\/span>
\ntwo units packed cells without incidence.<\/span>\u00a0Coumadin was placed on hold and the<\/span>
\npatient was placed on Lasix.<\/span>
\nPostoperatively the patient developed an atrial fibrillation whic<\/span>h was controlled<\/span>
\nwith Toprol, Digoxin, and Verapamil.<\/span>\u00a0Three days postoperatively, the patient<\/span>
\nbegin to spike fevers of 101<\/span>\u00a0\u030a.\u00a0Cultures were taken of the blood and urine.<\/span>\u00a0The<\/span>
\npatient<\/span>\u00a0developed a urinary tract<\/a> infection growing over 100,000 colonies of E.<\/span>
\nColi bacteria. The patient was started on Bactrim p.o. however the patient<\/span>
\ncomplained of a rash over her mid<\/span>–<\/span>abdomen.<\/span>\u00a0Calamine lotion was applied to the<\/span>
\nrash using cotton swabs.<\/span>\u00a0The medication was switched to Keflex.<\/span>\u00a0The patient is<\/span>
\nafebrile and currentl<\/span>y receiving physical therapy<\/a>.<\/span>\u00a0She will be transferred to<\/span>
\nMiami Dade College Rehab Center where she will continue her therapy.<\/span><\/p>\n
\nThe patient will be discharged to rehab with Lactulose 60 mg p.r.n. q.h.s.,<\/span>
\nDarvocet 1 tablet q..6h p.r.n.<\/span>, Lovothroid 0.075 mg q.d., Lipitor 10 mg q.d.,<\/span>
\nRemeron 15 md q.hs., OsCal 500+D 1 t.i.d., Coumadin 3 mg q.d., Diovan 160<\/span>
\nmg q.d., Magnesium chloride 400<\/span>–<\/span>1 t.i.d., Neutra<\/span>–<\/span>Phos 1 tab q.i.d., Megace 100<\/span>
\nmg q.i.d., Toprol 50<\/span>–<\/span>mg q.d.<\/span>
\nMark J. Curry, MD__<\/span>\u00a0Mark J. Curry, MD<\/span>
\nAttending Physician<\/span><\/p>\n<\/div>\nA Sample Answer For the Assignment: HIM 2433 MDC Reporting Adverse Reaction Question<\/strong><\/h2>\n
Title: <\/strong> HIM 2433 MDC Reporting Adverse Reaction Question<\/strong><\/h2>\n
\n
\n\n
\n \u00a0<\/strong><\/td>\n Excellent<\/strong><\/td>\n Good<\/strong><\/td>\n Fair<\/strong><\/td>\n Poor<\/strong><\/td>\n<\/tr>\n<\/thead>\n\n \n Main Postinga<\/strong><\/td>\n 45\u00a0(45%)\u00a0– 50\u00a0(50%)<\/p>\n 40\u00a0(40%)\u00a0– 44\u00a0(44%)<\/p>\n 35\u00a0(35%)\u00a0– 39\u00a0(39%)<\/p>\n 0\u00a0(0%)\u00a0– 34\u00a0(34%)<\/p>\n \n Main Post: Timeliness<\/strong><\/td>\n 10\u00a0(10%)\u00a0– 10\u00a0(10%)<\/p>\n 0\u00a0(0%)\u00a0– 0\u00a0(0%)<\/td>\n 0\u00a0(0%)\u00a0– 0\u00a0(0%)<\/td>\n 0\u00a0(0%)\u00a0– 0\u00a0(0%)<\/p>\n \n First Response<\/strong><\/td>\n 17\u00a0(17%)\u00a0– 18\u00a0(18%)<\/p>\n 15\u00a0(15%)\u00a0– 16\u00a0(16%)<\/p>\n 13\u00a0(13%)\u00a0– 14\u00a0(14%)<\/p>\n 0\u00a0(0%)\u00a0– 12\u00a0(12%)<\/p>\n \n Second Response<\/strong><\/td>\n 16\u00a0(16%)\u00a0– 17\u00a0(17%)<\/p>\n 14\u00a0(14%)\u00a0– 15\u00a0(15%)<\/p>\n 12\u00a0(12%)\u00a0– 13\u00a0(13%)<\/p>\n 0\u00a0(0%)\u00a0– 11\u00a0(11%)<\/p>\n \n Participation<\/strong><\/td>\n 5\u00a0(5%)\u00a0– 5\u00a0(5%)<\/p>\n 0\u00a0(0%)\u00a0– 0\u00a0(0%)<\/td>\n 0\u00a0(0%)\u00a0– 0\u00a0(0%)<\/td>\n 0\u00a0(0%)\u00a0– 0\u00a0(0%)<\/p>\n \n Total Points: 100<\/td>\n <\/td>\n<\/tr>\n \n <\/td>\n <\/td>\n <\/td>\n <\/td>\n <\/td>\n <\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n